

001/002
RECEIVED
CENTRAL FAX CENTER

JAN 16 2004

OFFICIAL

R U S H

Atty Docket No. 015280-343100US

PTO FAX NO.: 703-746-7647

ATTENTION: Examiner Yu, Misook
TELEPHONE NO.: 703-308-2454

Group Art Unit 1642

OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER Yu, Misook

CERTIFICATION OF FACSIMILE TRANSMISSION


I hereby certify that the following document in re Application of RYBAK and NEWTON, Application No. 09/622,613, filed August 17, 2000 for RECOMBINANT ANTI-TUMOR RNASE is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

1. Supplemental Response, page 6
(Please replace page 6 sent earlier today.)

Number of pages being transmitted, including this page: ~~5~~ 2

Dated: January 16, 2004


Malinda C. Dagit

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: 415-576-0200
Fax: 415-576-0300

Appl. No. 09/622,613
Supplemental Reseponse dated January 16, 2004
Reply to Office Action of July 3, 2003

PATENT

36. (previously presented) The pharmaceutical composition of claim 35, where said antineoplastic is Adriamycin.

37. (original) A pharmaceutical composition comprising a cytotoxic reagent, said cytotoxic reagent comprising a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:24 and SEQ ID NO:26 in a pharmaceutically acceptable carrier.

38. (original) A method of killing cancer cells comprising contacting cells to be killed with a ribonuclease expressed by recombinant DNA and having a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:24 and SEQ ID NO:26.

39. (original) A method of killing cancer cells comprising contacting cells to be killed with a cytotoxic reagent expressed by recombinant DNA, comprising a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:24 and SEQ ID NO:26 covalently linked to a ligand binding moiety, said ligand binding moiety directed against a cell surface antigen on the cancer cells.

40. (cancelled)

41. (original) The method of claim 39, wherein said ligand binding moiety is an antibody.

42. (original) The method of claim 41, wherein said antibody is a single chain antibody.

Claims 43 and 44 (cancelled)